HE-4 IS ADMIRABLE AND APPRECIABLE THAN CA-125 IN MONITORING OF EPITHELIAL OVARIAN CARCINOMA CANDIDATES

Shinymol* and Umesh Verma

ABSTRACT

The deadliest type of gynecological carcinoma is still EOC, which is identified by its late-stage identification and silent proliferation. To increase survival rates, it is essential to identify the illness early on and with accuracy. The use of tumor markers in the diagnosis and therapy of OC has become increasingly important. This paper explains whether serum concentrations of cancer antigen 125 (CA-125) and human epididymis protein 4 (HE-4) could predict the surgical outcome of EOC. It also examines the diagnostic significance of tumor markers such as CA-125 and HE-4. We also talked about the tumor marker's (HE-4) value in ovarian cancer (OC)patients, both during and after treatment. When used alone, the tumor marker CA-125 is related to poor specificity and low sensitivity, particularly in premenopausal women, for early or stage I disease. Serum HE-4 is a useful biomarker for differentiating benign ovarian disease from ovarian cancer, although it can be influenced by a number of variables, such as age, smoking, and pregnancy. Combining these indicators, or at least two or three of them, is advised for a high sensitivity and specificity early stage EOC diagnosis. HE-4 might be an efficient marker to monitor both during and following OC treatment. For follow-up observations, a complementary role for HE-4 and CA-125 measures was proposed. Numerous researches assessed the predictive role of HE-4 for surgical outcome in primary cytoreductive surgery. Based on results of all studies, HE-4 a high potential biomarker for surgical outcome may be useful in predicting primary treatment.

Keywords: Epithelial ovarian cancer, CA-125, HE-4, follow-up.